These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20398784)

  • 1. Protein delivery for retinal diseases: from basic considerations to clinical applications.
    El Sanharawi M; Kowalczuk L; Touchard E; Omri S; de Kozak Y; Behar-Cohen F
    Prog Retin Eye Res; 2010 Nov; 29(6):443-65. PubMed ID: 20398784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Applications of nanoparticles in ophthalmology.
    Diebold Y; Calonge M
    Prog Retin Eye Res; 2010 Nov; 29(6):596-609. PubMed ID: 20826225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel drug delivery systems for retinal diseases. A review.
    Lee SS; Robinson MR
    Ophthalmic Res; 2009; 41(3):124-35. PubMed ID: 19321933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel approaches to ocular drug delivery.
    Davis JL; Gilger BC; Robinson MR
    Curr Opin Mol Ther; 2004 Apr; 6(2):195-205. PubMed ID: 15195932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transscleral Coulomb-controlled iontophoresis of methylprednisolone into the rabbit eye: influence of duration of treatment, current intensity and drug concentration on ocular tissue and fluid levels.
    Behar-Cohen FF; El Aouni A; Gautier S; David G; Davis J; Chapon P; Parel JM
    Exp Eye Res; 2002 Jan; 74(1):51-9. PubMed ID: 11878818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug delivery systems for vitreoretinal diseases.
    Yasukawa T; Ogura Y; Tabata Y; Kimura H; Wiedemann P; Honda Y
    Prog Retin Eye Res; 2004 May; 23(3):253-81. PubMed ID: 15177203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug delivery to target the posterior segment of the eye].
    Behar-Cohen F
    Med Sci (Paris); 2004; 20(6-7):701-6. PubMed ID: 15329823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations.
    Loftsson T; Sigurdsson HH; Konrádsdóttir F; Gísladóttir S; Jansook P; Stefánsson E
    Pharmazie; 2008 Mar; 63(3):171-9. PubMed ID: 18444504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delivery of anti-angiogenic molecular therapies for retinal disease.
    Anderson OA; Bainbridge JW; Shima DT
    Drug Discov Today; 2010 Apr; 15(7-8):272-82. PubMed ID: 20184967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene delivery to the retina: focus on non-viral approaches.
    Naik R; Mukhopadhyay A; Ganguli M
    Drug Discov Today; 2009 Mar; 14(5-6):306-15. PubMed ID: 18973824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitreoretinal disease in the coming decade.
    Chiang A; Haller JA
    Curr Opin Ophthalmol; 2010 May; 21(3):197-202. PubMed ID: 20224401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rabbit model for assessing the ocular barriers to the transscleral delivery of triamcinolone acetonide.
    Robinson MR; Lee SS; Kim H; Kim S; Lutz RJ; Galban C; Bungay PM; Yuan P; Wang NS; Kim J; Csaky KG
    Exp Eye Res; 2006 Mar; 82(3):479-87. PubMed ID: 16168412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in non-viral ocular gene transfer.
    Peeters L; Sanders NN; Demeester J; De Smedt SC
    Biochem Soc Trans; 2007 Feb; 35(Pt 1):47-9. PubMed ID: 17233598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug delivery systems for the eye.
    Kearns VR; Williams RL
    Expert Rev Med Devices; 2009 May; 6(3):277-90. PubMed ID: 19419285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-viral ocular gene therapy: potential ocular therapeutic avenues.
    Bloquel C; Bourges JL; Touchard E; Berdugo M; BenEzra D; Behar-Cohen F
    Adv Drug Deliv Rev; 2006 Nov; 58(11):1224-42. PubMed ID: 17095114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stable rAAV-mediated transduction of rod and cone photoreceptors in the canine retina.
    Bainbridge JW; Mistry A; Schlichtenbrede FC; Smith A; Broderick C; De Alwis M; Georgiadis A; Taylor PM; Squires M; Sethi C; Charteris D; Thrasher AJ; Sargan D; Ali RR
    Gene Ther; 2003 Aug; 10(16):1336-44. PubMed ID: 12883530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety evaluation of ocular drug delivery formulations: techniques and practical considerations.
    Short BG
    Toxicol Pathol; 2008 Jan; 36(1):49-62. PubMed ID: 18337221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinal dysfunction in cancer-associated retinopathy is improved by Ca(2+) antagonist administration and dark adaptation.
    Ohguro H; Ogawa K; Maeda T; Maruyama I; Maeda A; Takano Y; Nakazawa M
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2589-95. PubMed ID: 11581204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
    Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.